Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13729018 | 0.83 | DRD1 (0.44) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 | |
| SCHEMBL161636 | 0.82 | IRAK4 (0.38) | KMT2AALDH1A1KCNN4POLBLMNA | |
| SCHEMBL899973 | 0.79 | DRD1 (0.35) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 | |
| SCHEMBL900244 | 0.78 | DRD1 (0.38) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 | |
| SCHEMBL3454325 | 0.78 | DRD1 (0.34) | KMT2ASMN1; SMN2HTTDRD1 | |
| SCHEMBL1067400 | 0.78 | NR1I2 (0.37) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 | |
| SCHEMBL1068394 | 0.78 | DRD1 (0.34) | KMT2ASMN1; SMN2HTTDRD1SLC6A2 | |
| SCHEMBL7683321 | 0.76 | HTT (0.38) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 | |
| SCHEMBL1567672 | 0.75 | KMT2A (0.30) | KMT2A | |
| SCHEMBL1064618 | 0.75 | HPGD (0.34) | KMT2ASMN1; SMN2HTTDRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | claimed |
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | claimed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | claimed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | claimed |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-12-29 | — | — | US | claimed |
| EP-3080113-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | claimed |
| WO-2015086526-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | claimed |
| EP-4017591-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3774741-B1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2022-06-08 | — | — | EP | disclosed |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | UCB Biopharma SRL (BE) | 2021-04-01 | — | — | US | disclosed |
| WO-2021032687-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3774741-A1 | ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES | UCB Biopharma SRL (BE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020191501-A1 | METHODS AND USES OF BEMITHYL AND DERIVATIVES FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS | ALGERNON PHARMACEUTICALS INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| CN-101902914-A | Azolylmethyloxiranes, use thereof and compositions comprising same | BASF SE | 2010-12-01 | — | — | CN | disclosed |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2235005-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2234488-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009077500-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077443-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | KMT2A 4258/4885SMN1; SMN2 1241/4885HTT 926/4885 |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | KMT2A 4258/4885SMN1; SMN2 1241/4885HTT 926/4885 |
| US-20210094941-A1 | Antimalarial Hexahydropyrimidine Analogues | G6PD, DPYD, DHODH | KMT2A 1415/4885SMN1; SMN2 3093/4885HTT 3884/4885 |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, SQOR, NOX5 | KMT2A 538/4885SMN1; SMN2 2481/4885HTT 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.